Moderna Therapeutics
IPO News: Filed S-1/A: Moderna Launches 21.7mm IPO with $22-$24 Marketing Range
Moderna Therapeutics

Last Wednesday, Moderna launched its 21.7mm share IPO with a $22-$24 marketing range. At the midpoint, the IPO is expected to raise $500mm in proceeds. Moderna’s major holders include Flagship Pioneering, AstraZeneca, Viking Global Equities and Timothy Springer and affiliated entities. The company intends to list on the NASDAQ under the ticker symbol MRNA.

Morgan Stanley, Goldman Sachs and J.P. Morgan are serving as active bookrunners on the transaction with Bank of America Merrill Lynch, Barclays, Piper Jaffray and Bryan, Garnier & Co. acting as passive bookrunners. Oddo BHF, Oppenheimer, Needham and Chardan round out the underwriting group as co-managers.

Moderna is creating a new category of transformative medicines based on messenger RNA, or mRNA, to improve the lives of patients. Their therapeutic and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases.

 

Moderna

NASDAQ:  MRNA

Initial Filing Date:  11/09/18

Launch Date:  11/28/18

Price Range:  $22.00 - $24.00

Shares Offered (Pre-Shoe | mm):  21.7

Primary Shares (mm):  21.7

Secondary Shares (mm):  0.0

Amount Offered (@ Midpoint)(mm):  $500.0

% Secondary:  0.0%

Shares Outstanding (mm):  324.4

Market Value at Midpoint (mm):  $7,461.5

Offering as % of Market Value:  6.7%

Active Bookrunners:  Morgan Stanley | Goldman Sachs | J.P. Morgan

Passive Bookrunners:  Bank of America Merrill Lynch | Barclays | Piper Jaffray | Bryan, Garnier & Co.

Co-Managers:  Oddo BHF | Oppenheimer | Needham | Chardan

Major Holders:  Flagship Pioneering | AstraZeneca | Viking Global Equities | Timothy Springer & Affiliates

Note:  Emerging Growth Company

 

Reference Link: S-1/A